16+
Major trials tracked
Immunology & inflammation · Live ClinicalTrials.gov data
Lebrikizumab (Ebglyss) clinical trial pipeline
The timeline below tracks the 16 largest phase 2–4 lebrikizumab trials on ClinicalTrials.gov by enrolment, 2 of them actively recruiting. The next phase 3 primary completion among them is expected Sept 2026. Refreshed daily — add up to four competitors to compare pipelines side by side.
14
Phase 3 trials
2
Actively recruiting
Sept 2026
Next phase 3 primary completion
8,433
Participants across trials
Eli Lilly and Company
Lead sponsor by trial count
lebrikizumab (16)7 active2013–2029
lebrikizumab
'13
'15
'17
'19
'21
'23
'25
'27
'29
lebrikizumab
A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller MedicationP3
A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller MedicationP3
A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller MedicationP3
A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)P2
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate AsthmaP3
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)P2
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)P3
ADvocate2P3
ADjoinP3
ADvantageP3
ADorable-1P3
ADorable-2P3
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic DermatitisP3
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)P3
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)P3
ADhope 2P3
Upcoming readouts
4 ahead · lebrikizumab
Select a trial to load its full ClinicalTrials.gov record.
Key lebrikizumab trials
Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06339008 | A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) | Phase 3 | Recruiting | Sept 2026 |
| NCT06338995 | A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With … | Phase 3 | Recruiting | May 2027 |
| NCT06280716 | A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderat… | Phase 3 | Active, not recruiting | Sept 2025 |
| NCT05559359 | ADorable-1 — A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopi… | Phase 3 | Active, not recruiting | Jan 2026 |
| NCT06526182 | ADhope 2 — A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis | Phase 3 | Active, not recruiting | Apr 2027 |
| NCT05735483 | ADorable-2 — A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <1… | Phase 3 | Enrolling by invitation | Dec 2027 |
| NCT02104674 | A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma | Phase 3 | Completed | May 2016 |
| NCT01867125 | A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Seco… | Phase 3 | Completed | Jan 2017 |
| NCT01868061 | A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Contr… | Phase 3 | Completed | Jan 2017 |
| NCT04146363 | Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADv… | Phase 3 | Completed | Jun 2021 |
| NCT04178967 | ADvocate2 — Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis | Phase 3 | Completed | Jul 2021 |
| NCT05149313 | ADvantage — A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) Th… | Phase 3 | Completed | Jan 2023 |
Related drug pipelines
FAQ
- How many clinical trials are running for lebrikizumab?
- ClinicalTrials.gov lists more than 16 phase 2–4 lebrikizumab trials. This page tracks the 16 largest by enrolment: 2 phase 2, 14 phase 3, and 0 phase 4 among them, with 2 actively recruiting. Updated daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare lebrikizumab against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.